buspirone has been researched along with Atrophy in 2 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine1A (5-HT1A) agonist, in a homogenous group of patients characterized by the same well-defined single condition, cerebellar cortical atrophy." | 9.08 | Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. ( Adeleine, P; Dumas, R; Honnorat, J; Laurent, B; Michel, D; Nighoghossian, N; Trouillas, P; Vighetto, A; Xie, J, 1997) |
| "To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine1A (5-HT1A) agonist, in a homogenous group of patients characterized by the same well-defined single condition, cerebellar cortical atrophy." | 5.08 | Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. ( Adeleine, P; Dumas, R; Honnorat, J; Laurent, B; Michel, D; Nighoghossian, N; Trouillas, P; Vighetto, A; Xie, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trouillas, P | 2 |
| Xie, J | 2 |
| Adeleine, P | 2 |
| Michel, D | 1 |
| Vighetto, A | 1 |
| Honnorat, J | 1 |
| Dumas, R | 1 |
| Nighoghossian, N | 1 |
| Laurent, B | 1 |
2 trials available for buspirone and Atrophy
| Article | Year |
|---|---|
Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia.
Topics: Anxiety; Atrophy; Buspirone; Cerebellar Ataxia; Cerebellar Cortex; Cerebellum; Humans; Middle Aged; | 1997 |
Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
Topics: Adult; Atrophy; Buspirone; Cerebellar Ataxia; Cerebellum; Double-Blind Method; Humans; Middle Aged; | 1997 |